Arch Fam Med
Institution: STANFORD Univ Med Center  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 2 No. 9, September 1993 TABLE OF CONTENTS
  •  Online Features
  Original Contributions
 This Article
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Terazosin in the Treatment of Benign Prostatic Hyperplasia

Michael K. Brawer, MD; George Adams, MD; Howard Epstein, MD; the Terazosin Benign Prostatic Hyperplasia Study Group

Arch Fam Med. 1993;2(9):929-935.

Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.

1. Caine M, Pfau A, Perlberg S. The use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48:255-264. PUBMED
2. Caine M. Alpha-adrenergic mechanisms in dynamics of benign prostatic hypertrophy. Urology. 1988;32(suppl):16-26. PUBMED
3. Lepor H. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:651-659. PUBMED
4. Lepor H, Knapp-Maloney G, Sunshine H. A dose titration study evaluating terazosin, a selective, once-a-day {alpha}1-blocker for the treatment of symptomatic benign hyperplasia. J Urol. 1990;144:1393-1398. PUBMED
5. Lepor H, Knapp-Maloney G, Wozniak-Petrofsky J. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. Int J Clin Pharmacol Ther Toxicol. 1989;27:392-397. PUBMED
6. Fabricius PG, Weizert P, Dunzendorfer U, Mac Hannaford J, Maurath C. Efficacy of once-a-day terazosin in benign prostatic hyperplasia: a randomized, double-blind placebo-controlled clinical trial. Prostate. 1990;3(suppl):85-93.
7. Dunzendorfer U. Clinical experience: symptomatic management of BPH with terazosin. Urology. 1988;32(suppl):27-31. PUBMED
8. Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo controlled, multicentered study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992;148:1467-1474. PUBMED
9. Boyarsky S, Jones G, Paulson D, Prout G. A new look at bladder obstruction by the Food and Drug Administration regulators: guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg. 1977;68:29-32.
10. von Garrelts B. Micturition in the normal male. Acta Chir Scand. 1957;114:197-210.
11. Siroky MB, Olsson CA, Krane RJ. The flow rate nomogram, II: clinical correlation. J Urol. 1980;123:208-210. PUBMED
12. Siroky MS, Olsson CA, Krane RJ. The flow rate nomogram, I: development. J Urol. 1979;122:665-668. PUBMED
13. Lepor H. Alpha1-adrenergic blockers in the medical management of benign pro-static hyperplasia. Curr Opin Urol. 1992;2:26-29.
14. Hedlund H, Andersson HE, Ek A. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 1983;130:275-278. PUBMED
15. Kirby RS, Coppinger SWC, Corcoran MO, Chapple CR, Flannigan M, Milroy EJG. Prazosin in the treatment of prostatic obstruction: a placebo-controlled study. BrJ Urol. 1987;60:136-142.
16. Chapple CR, Christmas TJ, Milroy EJ. A twelve-week placebo-controlled study of prazosin in the treatment of prostatic obstruction. Urol Int. 1990;45(suppl):47-55. PUBMED
17. Mantorana G, Giberti C, Damonte P, Ciprandi G, Dirienzo W, Giulana L. The effect of prazosin in benign hypertrophy: a placebo controlled double-blind study. Int Res Commun Sci J Med Sci. 1984;12:11.
18. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50:551-554. PUBMED
19. Gerstenberg T, Blaajerg J, Nielson ML, Clausen S. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia: a urodynamic investigation. Invest Urol. 1980;18:29-31. PUBMED
20. Brooks ME, Sidi AA, Hanani Y, Braf KF. Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy: a controlled study. Urology. 1983;21:474-478. PUBMED
21. Ferrie BG, Paterson PJ. Phenoxybenzamine in prostatic hypertrophy: a double-blind study. Br J Urol. 1987;59:63-65. PUBMED
22. Abrams PH, Shah PJ, Stone R, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol. 1982;54:527-530. PUBMED
23. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-1191. ABSTRACT
24. Lange PH. Is the prostate pill finally here? N Engl J Med. 1992;327:1234-1236. PUBMED
25. Luther RR. New perspectives on selective alpha 1 blockade. Am J Hypertens. 1989;2:729-735. PUBMED
26. Cohen JD. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents. Am Heart J. 1991;122:919-925. PUBMED